06) and with a significant difference from the BCP-OM group (P=0.01). BCP-CM and BCP-OM groups were homogeneous throughout the experimental period (P=0.59).
BCP incorporated into SHED cultures showed promising outcomes, albeit less pronounced than autogenous grafting, for the repair of rat calvarial defects.
BCP incorporated into SHED cultures showed to be an alternative in view of the disadvantages to obtain autogenous bone graft.
BCP incorporated into SHED cultures showed to be an alternative in view of the disadvantages to obtain autogenous bone graft.The data on long-term outcome in enthesitis-related arthritis (ERA), the commonest category of JIA in India, is scant. https://www.selleckchem.com/products/danirixin.html Thus, we studied outcomes of ERA in a resource-constrained setting.
Patients with ERA (ILAR classification) (??5years of disease and???18years) were included. Data on clinical features, Bath indices (BASMI, BASDAI, BASFI), ASDAS, and health assessment questionnaire-disability index (HAQ-DI) was collected. X-ray pelvis including hips was obtained and compared with baseline X-ray for progression of sacroiliitis and hip arthritis. Fulfillment of adult criteria of spondyloarthropathy (SpA) were also assessed.
Seventy-three 73 patients (72 males) of median age 20 (18-23) years and disease duration 8 (5.5-11) years were recruited. There was delay in diagnosis of 4 (1.75-6) years. Thirty-nine (53%) had BASDAI???4 and 63 (91%) had ASDAS-CRP?&gt;?1.3. Two-third (60%) had functional disability (HAQ-DI???0.5). Poor outcome (BASDAI???4, ASDAS?&gt;?2.1, BASFI?&gt;?0.9, or HAQ-DI???0.5) was seen in tients and hip involvement, presence of HLA B27, and axial involvement were the predictors of poor outcome.
Most ERA patients had active disease in adulthood. Hip involvement, axial involvement, and HLA-B27 positivity were predictors of poor outcome. Key Points ? Almost 90% of adults with ERA had active disease even after 8 years of disease. ? Poor outcomes were seen in three-fourths of patients and hip involvement, presence of HLA B27, and axial involvement were the predictors of poor outcome.In the medical literature, there are only a few references on refractory fibromyalgia and there is no consensus definition available on this concept. Some definitions of refractory fibromyalgia have been proposed based on the lack of response to a number of medications, and perhaps the most appropriate term is treatment-refractory fibromyalgia. To achieve the definition of treatment-refractory fibromyalgia, it is necessary to consider several previous steps, such as making sure the diagnosis has been made properly and a differential diagnosis with entities that can mimic fibromyalgia symptoms (including complete physical examination and laboratory test) has been made. The possibility that another factor that alters the response to treatment should be investigated, and in particular review all prescribed medication and search for some non-medical reasons that could mask the response to treatment (e.g., legal compensation). The definition of refractory fibromyalgia is complex and probably should include a lack of response to a specified number of drugs or to combination therapy with at least two non-pharmacological measures. In this article, it is not our purpose to present a formal definition, but to raise the possible bases for this purpose. We believe that it is a subject that must be discussed extensively before reaching a consensus definition. Key Points ? There is no appropriate definition to classify fibromyalgia patients who do not respond to the usual pharmacological and non-pharmacological measures according to the national or international guidelines. ? A consensus definition is required to classify these patients, which could help standardize future management strategies. In this article, we propose the bases on which refractory fibromyalgia could be defined.We report a new thoracoscopic surgical skill training and assessment system with automatic scoring techniques, the Huaxi Intelligent Thoracoscopic Skill Training and Assessment (HITSTA) system. We also evaluated the discriminative ability of this system compared to our conventional scoring method at our institution.
We retrospectively collected training data of thoracic board-certified thoracic surgeons at West China Hospital, Sichuan University from January 1, 2018 to January 1, 2019. Surgeons were assessed by HITSTA system and human examiners simultaneously. Total scores were summed from 3 tasks (grasping with delivery, pattern cutting, and suture with knot). Bland-Altman analysis was used to test agreement of scores made by HITSTA system (automatic scoring) and human examiners (manual scoring). Differentiation ability was also compared between the two scoring methods.
Thirty-nine surgeons were recruited. Scores made by HITSTA system and human examiners were not consistent. For suture with knot, automatic scoring method could detect the score differences between different training status (trained 26.92?±?12.04, untrained 19.85?±?11.12; p?=?0.026) and training duration (&lt;?10h 20.67?±?15.23, ???10h 31.92?±?5.56; p?=?0.003). For total scores, automatic scoring approach could discriminate between different training status (trained 71.90?±?12.63; untrained 61.41?±?13.87; p?=?0.016) and training duration (&lt;?10h 65.23?±?15.31; ???10h 77.23?±?6.94; p?=?0.046).
HITSTA system could discriminate the different levels of thoracoscopic surgical skills better than the traditional manual scoring method. Larger prospective studies are warranted to validate the differentiation ability of HITSTA system.
HITSTA system could discriminate the different levels of thoracoscopic surgical skills better than the traditional manual scoring method. Larger prospective studies are warranted to validate the differentiation ability of HITSTA system.Transanal total mesorectal excision (TaTME) appears to have favorable surgical and pathological outcomes. However, the evidence on survival outcomes remains unclear. We performed a meta-analysis to compare long-term oncologic outcomes of TaTME with transabdominal TME for rectal cancer.
PubMed, EMBASE, and the Cochrane Library were searched. Data were pooled, and overall effect size was calculated using random-effects models. Outcome measures were overall survival (OS), disease-free survival (DFS), and local and distant recurrence.
We included 11 nonrandomized studies that examined 2,143 patients for the meta-analysis. There were no significant differences between the two groups in OS, DFS, and local and distant recurrence with a RR of 0.65 (95% CI 0.39-1.09, I?=?0%), 0.79 (95% CI 0.57-1.10, I?=?0%), 1.14 (95% CI 0.44-2.91, I?=?66%), and 0.75 (95% CI 0.40-1.41, I?=?0%), respectively.
In terms of long-term oncologic outcomes, TaTME may be an alternative to transabdominal TME in patients with rectal cancer.